• Users Online: 553
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Browse Articles Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
LETTER TO EDITOR
Year : 2022  |  Volume : 13  |  Issue : 1  |  Page : 145

Fenofibrates: A safe and novel weapon against coronavirus-induced lung fibrosis


Department of Dermatology, Molecular Dermatology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Date of Submission21-Sep-2020
Date of Acceptance15-Jan-2021
Date of Web Publication28-Nov-2022

Correspondence Address:
Mohammad Mahdi Parvizi
Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, Zand Avenue, Shahid Faghihi Hospital, Shiraz - 7134844119
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijpvm.IJPVM_566_20

Rights and Permissions

How to cite this article:
Namazi MR, Parvizi MM. Fenofibrates: A safe and novel weapon against coronavirus-induced lung fibrosis. Int J Prev Med 2022;13:145

How to cite this URL:
Namazi MR, Parvizi MM. Fenofibrates: A safe and novel weapon against coronavirus-induced lung fibrosis. Int J Prev Med [serial online] 2022 [cited 2023 Jan 31];13:145. Available from: https://www.ijpvmjournal.net/text.asp?2022/13/1/145/362063



Dear Editor,

Coronavirus-19 is a novel virus involving humans and animals in the world.[1] According to chest radiography and chest computerized tomography (CT) scan, the lungs of patients with COVID-19 are infiltrative prone to lung fibrosis that may result in death.[2] Therefore, prevention and early treatment of lung fibrosis are critical.

The infection, as well as Coronavirus-19, causes a surge in the production of IL-6, which is known to potently induce fibrosis via a STAT-3 dependent pathway.[3] Therefore, blocking the fibrosis pathway can be a way to prevent lung fibrosis, as well as morbidity and mortality of the disease.

Fenofibrates are fibric acid derivative used for dyslipidemia, hypercholesterolaemia, and hypertriglyceridaemia.[4] According to the literature, these drugs reduce C-reactive protein, fibrinogen, immunoglobulin G, tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), and interleukin-6 (IL-6) and inhibit the STAT3 pathway.[5],[6] Literature showed that gemfibrozil, a fenofibrate which used a lot, had significant effects in treatment of influenza and decrease in mortality rate due to this disease in mice model and these effects of fenofibrates were more remarkable in comparison with statin simvastatin.[7]

In conclusion, there are several evidence that show the main cause of death due to COVID-19 is lung damage, lung fibrosis, and impaired ventilation. Therefore, it seems that phenofibrates can be a good choice to prevent lung fibrosis and death in patients with COVID-19.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Kutti-Sridharan G, Vegunta R, Vegunta R, Mohan BP, Rokkam VR. SARS-CoV2 in different body fluids, risks of transmission, and preventing COVID-19: A comprehensive evidence-based review. Int J Prev Med 2020;11:97.  Back to cited text no. 1
  [Full text]  
2.
Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease-19 (COVID-19): Relationship to duration of infection. Radiology 2020;295:200463.  Back to cited text no. 2
    
3.
Epstein Shochet G, Brook E, Bardenstein-Wald B, Shitrit D. TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling. Respiratory Research. 2020;21.  Back to cited text no. 3
    
4.
Keating GM, Croom KF. Fenofibrate. Drugs 2007;67:121-53.  Back to cited text no. 4
    
5.
Wahba MG, Messiha BA, Abo-Saif AA. Protective effects of fenofibrate and resveratrol in an aggressive model of rheumatoid arthritis in rats. Pharm Biol 2016;54:1705-15.  Back to cited text no. 5
    
6.
Lv J, Wang X, Liu S, Liang P, Feng M, Zhang L, et al. Protective effect of Fenofibrate in renal ischemia reperfusion injury: Involved in suppressing kinase 2 (JAK2)/transcription 3 (STAT3)/p53 signaling activation. Pathol Biol 2015;63:236-42.  Back to cited text no. 6
    
7.
Alleva L, Budd A, Clark I. Minimising influenza disease with fibrates. Int J Infect Dis 2008;12:e176.  Back to cited text no. 7
    




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
References

 Article Access Statistics
    Viewed258    
    Printed12    
    Emailed0    
    PDF Downloaded21    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]